Optima to host post-conference workshop at Lyophilization USA

SMi Group23 - 24 October 2019, Boston, USA.
Delegates for the 5th Annual Lyophilization USA conference, taking place in Boston, will have the opportunity to attend the half-day post-conference workshop titled "Current and Future Freeze-Drying Technologies and Methods" led by Dena Flamm and Alexander Tambovzev on October 25th 2019.

Overview of the workshop

Freeze dried products are well established in the market with an increasing trend in aseptically produced lyophilized products, including peptides and proteins. This workshop will give delegates an introduction into the Physics and Thermodynamics of Freeze-Drying; including both presentation of topics and an open discussion within the group. The session will support a better understanding of the Freeze-Drying process with the different methods available in the marketas well as discuss an alternative Freeze-Drying process for consideration.

Benefits of Attending

Delegates will have the opportunity to engage in an in-depth discussion with industry experts from Optima on the latest technological developments in the Lyophilization industry. They will also gain a better understanding of the most up to date freeze-drying technology available on the market, as well as what the future of this field looks like.

This workshop will enhance delegate's knowledge on controlled nucleation, available PAT's and the future of flexible PAT processes, and alternative freeze-drying technologies including spray drying, spin freeze-drying and microwave drying.

The brochure with the full conference program and workshop information is available to download online at http://www.lyophilisation-usa.com/PR3

Workshop Leader Overview

Dena Flamm is a Business Development Manager for OptimaMachinery Corporation. She is responsible for freeze dryer development in the North American market and has over 17 years of experience in the pharmaceutical industry. Studies include, an MBA in International Management from the University of St. Thomas with an undergraduate degree in Business and Physics.

Alexander Tambovzev is a Project Engineering and Development Group Leader at Optima Pharma, Germany. The area of his responsibility is leading the project engineering of the freeze dryers as well as the R&D effort in the freeze dryer technology. In 2008, Alexander received a Ph.D. in refrigeration technology from the Technical University of Dresden with a focus on the modelling of dynamic processes. He has worked in the research and development area of refrigeration systems for commercial and industrial applications.

An early bird saving of $200 is available for bookings placed before the 30th August. Registrations can be made online at http://www.lyophilisation-usa.com/PR3

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...